Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardent Health, Inc. filings document the formal reporting record for a public healthcare provider operating acute care hospitals and related sites of care through subsidiaries. Form 8-K disclosures furnish quarterly operating results, including revenue, admissions measures, net patient service revenue, adjusted EBITDA, and related non-GAAP reconciliations.
The filing record also covers governance and capital-structure matters. Proxy materials describe annual-meeting proposals, director elections, executive compensation, equity awards, and pay-versus-performance data. Other 8-K filings report executive-separation and severance arrangements, a common stock repurchase authorization, and amendments to term loan and asset-based lending credit agreements involving subsidiary borrowers and guarantors.
Ardent Health, Inc. reported that director Robert DeMichiei received a grant of 14,231 restricted stock units representing its common stock. The award was granted at no cash cost and vests in full on the first anniversary of April 1, 2026, contingent on his continued service. Following this equity grant, he directly holds 24,304 shares of Ardent Health common stock. Restricted stock units are a form of share-based compensation that convert into shares when vesting conditions are met, aligning the director’s interests with long-term company performance.
GOODYEAR WILLIAM M reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director William M. Goodyear received a grant of 14,231 shares of common stock in the form of restricted stock units at no cost. These units vest in full on the first anniversary of April 1, 2026, if he remains in service with the company. Following this award, he directly holds 115,367 shares of Ardent Health common stock.
Campion Suzanne reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Suzanne Campion reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units. These units vest in full on the first anniversary of April 1, 2026, if she continues serving with the company through that date. After this award, she directly holds 58,215 shares of common stock, reflecting a routine equity-based compensation grant rather than an open-market purchase.
BYNOE PETER C B reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Peter C. B. Bynoe reported an equity award of 14,231 shares of Common Stock, received as a grant at no cash cost per share. These are restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to his continued service. Following this award, he holds 115,367 shares directly.
Ardent Health, Inc. Chief Operating Officer Dave Caspers received an equity award of 35,673 shares of Common Stock on April 1, 2026 as a grant or award. The award represents restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service with the company.
On the same date, 2,684 shares were withheld at $8.67 per share to cover tax obligations in accordance with Rule 16b-3, a routine tax-withholding disposition rather than an open-market sale. After these transactions, Caspers directly owned 35,604 shares of Common Stock.
Ardent Health EVP, GC and Secretary Stephen C. Petrovich received a grant of 24,904 shares of common stock as restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to continued service. To cover tax obligations on RSU vesting, 1,425 shares on March 31, 2026 at $8.56 and 1,808 shares on April 1, 2026 at $8.67 were withheld rather than sold on the open market. Following these compensation-related transactions, he holds 774,707 shares directly, and 186,225 shares are reported as indirectly held in family GST‑2016 Exempt Family Trusts for which he disclaims beneficial ownership except for any pecuniary interest.
Ardent Health, Inc. senior vice president and chief accounting officer David Raynor reported routine equity compensation activity in the company’s stock. On April 1, 2026 he received a grant of 11,538 shares of common stock at no cost, tied to restricted stock units that vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service. To cover taxes owed on RSU vesting, 924 shares were withheld on April 1, 2026 at $8.67 per share and 819 shares were withheld on March 31, 2026 at $8.56 per share, consistent with Rule 16b-3 treatment rather than open‑market sales. Following these transactions, Raynor directly owned 130,445 shares of Ardent Health common stock.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine reported routine equity compensation activity in common stock. On April 1, 2026, he received a grant of 53,846 shares, representing restricted stock units that vest in three equal installments from April 1, 2026. To cover taxes on RSU vesting, the company withheld 2,510 shares on March 31, 2026 at $8.56 per share and 4,381 shares on April 1, 2026 at $8.67 per share under Rule 16b-3. Following these transactions, he directly holds 319,183 common shares.
Ardent Health, Inc. President and CEO Martin Bonick reported compensation-related stock activity involving restricted stock units and associated tax withholding.
On April 1, 2026, he received 134,615 shares of common stock as a grant or award. These restricted stock units vest in three substantially equal installments on each anniversary of April 1, 2026, subject to his continued service with the company.
To cover tax obligations upon vesting of restricted stock units under Rule 16b-3, 10,952 shares were withheld at a reference price of $8.67 per share on April 1, 2026 and 8,026 shares were withheld at $8.56 per share on March 31, 2026. Following these transactions, Bonick directly owned 1,437,937 shares of Ardent Health common stock.
Ardent Health, Inc. reported that Ethan Chernin, its President, Hospital Services, departed the company effective March 24, 2026. The company classified his departure as a “Qualifying Termination” under its Executive Severance Plan, meaning he will receive severance and related benefits subject to that plan’s terms.
Details of the severance framework are described in Ardent Health’s 2025 proxy statement and in the Executive Severance Plan previously filed as an exhibit to a Form 10-Q for the quarter ended June 30, 2024.